- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT04876053
Consegna di cibo a domicilio per la gestione del diabete nei pazienti delle cliniche rurali
Il nostro obiettivo a lungo termine è trasformare la gestione del T2DM da parte dei residenti rurali. L'obiettivo di questo studio è determinare l'efficacia di un intervento che sia scalabile e sostenibile e promuova l'adesione del paziente mitigando le difficoltà dei partecipanti rurali con insicurezza alimentare associate al completamento degli interventi esistenti. I nostri obiettivi specifici sono:
- Confronta l'efficacia dell'Healthy Food Delivery Intervention (HFDI) più le cure standard e le cure standard da sole per migliorare i risultati correlati al diabete tra i pazienti con insicurezza alimentare rurale con T2DM. Ipotesi: rispetto alla sola cura standard, i pazienti che ricevono l'HFDI più la cura standard dimostreranno un miglioramento: controllo glicemico H1 misurato da HbA1c; Fattori di rischio cardio-metabolico H2: pressione arteriosa, glicemia a digiuno, lipidi a digiuno e BMI; H3 autogestione: autoefficacia, aderenza a comportamenti di autogestione e aderenza ai farmaci; Risultati H4 centrati sul paziente: disagio correlato al diabete, qualità della vita correlata al diabete e complicanze correlate al diabete.
- Confronta l'efficacia dell'HFDI più cure standard e cure standard da sole per migliorare la qualità della dieta tra i pazienti con insicurezza alimentare rurale con T2DM. Ipotesi: rispetto alle sole cure standard, i pazienti che ricevono l'HFDI più le cure standard dimostreranno un miglioramento di: punteggi H1 Healthy Eating Index 2015 (HEI-2015); H2 consumo di frutta e verdura.
- Confronta il rapporto costo-efficacia per comprendere l'HFDI più i costi delle cure standard in relazione ai risultati in relazione alle sole cure standard. Ipotesi: l'HFDI sarà conveniente in base al costo tradizionale per anno di vita aggiuntivo aggiustato per la qualità guadagnato.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Type 2 diabetes mellitus (T2DM) is a growing public health concern affecting 37.3 million people (11.3%) in the United States (US). At the same time, 13.5 million (10.2%) US households experience food insecurity. People living in rural areas are particularly challenged by the intersection of food insecurity and T2DM - both food insecurity and T2DM prevalence in rural areas are higher than metropolitan areas. Arkansas has the sixth highest proportion of rural population (44.5%) of all US states, with rates of food insecurity and T2DM of 14.7% and 12.5%, respectively. Rurality and food insecurity are associated with social determinants of health that impede diabetes management (e.g., limited transportation, longer distance to healthcare clinics, lack of access to healthy food options). People experiencing food insecurity have poor diet quality (e.g., high intake of sugar-sweetened beverages and red/processed meat, low intake of fruits and vegetables), which is a key risk factor for unmanaged T2DM. Unmanaged T2DM can lead to increased risk of serious complications. Improved diet quality is a crucial factor to enhance T2DM management. Millions of people with T2DM experiencing food insecurity turn to food pantries for food; however, food pantries are not a long-term solution to improve health for rural people with T2DM experiencing food insecurity. Certified Diabetes Care and Education Specialists (CDCES; i.e., diabetes educators) have expertise in working with patients to instill knowledge and skills necessary to live an active and healthy lifestyle with T2DM.
This study used a two-arm randomized controlled comparative effectiveness design to compare the effectiveness of a Healthy Food Delivery Intervention (HFDI) plus a consultation with a CDCES Consultation Only in improving diabetes-related outcomes among rural people with T2DM experiencing food insecurity. We hypothesized HFDI to be comparatively more effective in improving HbA1c and other outcomes for rural people with T2DM experiencing food insecurity.
The primary outcome was change in hemoglobin A1c (HbA1c) between baseline and post-intervention. Secondary outcomes included diet quality (Healthy Eating Index-2015 and Veggie meter scores), body mass index, blood pressure, lipids, glucose, diabetes management self-efficacy and diabetes-related distress. We also examined the duration of treatment effects by comparing outcomes at 6 months post-intervention and 12 months post-intervention.
Participants were randomly assigned to either the HFDI arm or the CDCES Consultation Only arm. Participants randomized to the CDCES Consultation Only study arm received the standard of care at the clinic from which they were recruited, plus a 60 minute healthy eating consultation with a CDCES and a food pantry resource guide specific to their community. In addition to standard of care and the CDCES consultation, participants randomized to the HFDI arm received weekly home delivery of type 2 diabetes-appropriate food boxes over 3 months (12 food boxes in total). Each food box included approximately 9000 calories of food. Food boxes were designed by a Registered Dietician. Food boxes also included recipes and cooking tips specific to foods included in that week's box.
Participants were initially recruited only from family medicine clinics within the University of Arkansas for Medical Sciences (UAMS) network that serve the highest percentage of rural patients with T2DM. Additional clinics and Federally Qualified Health Centers were added as recruitment sites in order to meet study recruitment goals.
Inclusion criteria included: 1) 18 years of age or older; 2) food insecure (Hunger Vital Sign™ 2-item screener); 3) HbA1c ≥ 6.5%; 4) speak English or Spanish; and 5) live at a rural address. Note: the food insecurity and rural residence criteria were removed during the course of the study in order to meet study recruitment goals.
Exclusion criteria included: 1) having conditions making it unlikely the participant will be able to follow the protocol, such as terminal illness, severe mental illness, severely impaired vision or hearing, eating disorder, or plans to move out of the geographic region; 2) pregnant; 3) only one adult with T2DM per household was allowed to enroll.
Investigators worked with clinical stakeholders at each clinic site to ensure the study was integrated into existing workflows. Study flyers were placed throughout the clinics, in the exam rooms, and in the clinic waiting areas. All clinics had electronic health record systems that were queried monthly for recruitment. Research coordinators at each clinic site identified potential participants by reviewing monthly patient queries and daily clinic schedules. The research coordinators provided study information to potential participants in a pre-visit call or during the clinical visit. If the patient was interested, the research coordinator scheduled a 30-minute meeting to discuss the study and conduct eligibility screening in a private room in the clinic. Research staff were trained to flag potential participants that may not meet eligibility, which were then sent to the study physician for medical determination. Those deemed eligible to participate reviewed study information with the research coordinator, were given the chance to ask questions, and signed an informed consent. All recruitment and consent information was available in English and Spanish.
Randomization was conducted by the study biostatistician, who had no interactions with potential participants and no supervisory role with study staff responsible for recruiting, consent, and intervention processes. Stratified random assignment using permuted blocks of size 2, 4, and 6 was used to randomize participants 1:1 to the treatment arms using lists created with the blockrand R package. Strata of participant sex, level of T2DM control (6.5-9.0%; >9.0%), and age group (18-64; 65+ years) were used to ensure that similar numbers within each characteristic are assigned 1:1 to the treatment arms.
Data collection occurred in-person at the clinic from which participants were recruited, co-occurring with participants' primary care provider visits when possible. Biometric and survey measure outcomes were collected at baseline (pre-intervention), immediate post-intervention (approximately 12 weeks after baseline), 6 months post-intervention, and 12 months post-intervention.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Arkansas
-
Batesville, Arkansas, Stati Uniti, 72501
- UAMS - North Central
-
Corning, Arkansas, Stati Uniti, 72422
- Pocahontas Medical Center
-
Eureka Springs, Arkansas, Stati Uniti, 72632
- Washington Regional Medical Center
-
Fayetteville, Arkansas, Stati Uniti, 72703
- Washington Regional Medical Center
-
Fayetteville, Arkansas, Stati Uniti, 72703
- UAMS - Northwest
-
Fort Smith, Arkansas, Stati Uniti, 72901
- UAMS - West
-
Harrison, Arkansas, Stati Uniti, 72601
- Washington Regional Medical Center
-
Helena, Arkansas, Stati Uniti, 72390
- UAMS - East
-
Jonesboro, Arkansas, Stati Uniti, 72401
- UAMS - Northeast
-
Magnolia, Arkansas, Stati Uniti, 71753
- UAMS - South
-
Marianna, Arkansas, Stati Uniti, 72360
- Lee County Cooperative Clinic
-
Marshall, Arkansas, Stati Uniti, 72650
- Boston Mountain Rural Health Center
-
Pocahontas, Arkansas, Stati Uniti, 72455
- Pocahontas Medical Clinic
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Descrizione
Criterio di inclusione:
- 18 anni o più
- segnalare l'insicurezza alimentare
- refertare T2D (confermato dall'avere un HbA1c uguale o superiore a 6,5 alla raccolta dati iniziale immediatamente dopo il consenso)
- Parla inglese o spagnolo
- Attualmente vive in un indirizzo rurale
Criteri di esclusione:
- condizioni che rendono improbabile che il partecipante sia in grado di seguire il protocollo, come malattia terminale, grave malattia mentale, vista o udito gravemente compromessi, disturbi alimentari o piani per trasferirsi fuori dalla regione geografica
- Incinta
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Terapia di supporto
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Comparatore attivo: CDCES Consultation Only
Participants randomized to this study arm receive the standard of care at the clinic from which they were recruited, plus a 60 minute healthy eating consultation with a Certified Diabetes Care and Education Specialist and a food pantry resource guide specific to their community.
|
Participants randomized to this study arm receive the standard of care at the clinic from which they were recruited, plus a 60 minute healthy eating consultation with a Certified Diabetes Care and Education Specialist and a food pantry resource guide specific to their community.
|
|
Sperimentale: Healthy Food Delivery Intervention
In addition to standard of care and the CDCES consultation, participants randomized to the Healthy Food Delivery arm receive weekly home delivery of type 2 diabetes-appropriate food boxes over 3 months (12 food boxes in total).
|
Participants randomized to the Healthy Food Delivery Intervention receive standard of care, a CDCES Consultation, food pantry resource guide, and weekly home delivery of type 2 diabetes-appropriate food boxes over 3 months (12 food boxes in total).Each food box included approximately 9000 calories of food.
Food boxes were designed by a Registered Dietician.
Food boxes also included recipes and cooking tips specific to foods included in that week's box.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Hemoglobin A1c (HbA1c)
Lasso di tempo: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
Finger stick blood collection will be used to test HbA1c using a Siemens DCA Vantage analyzer.
|
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Diet Quality: Healthy Eating Index-2015 Score
Lasso di tempo: Baseline; Immediate post-intervention (approx. 12 weeks)
|
Diet quality was assessed with a 24-hour dietary recall interview using the Nutrition Data System for Research (NDSR) software.
The Healthy Eating Index-2015 (HEI) was applied to the dietary recall data to measure the extent that dietary intake among participants met the Dietary Guidelines for Americans 2015-2020 recommendations.
HEI-2015 consists of 13 individual components.
HEI-2015 scores have a possible range of 0-100, with higher numbers indicating better diet quality.
|
Baseline; Immediate post-intervention (approx. 12 weeks)
|
|
Diet Quality: Veggie Meter Score
Lasso di tempo: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
Skin carotenoid level was measured using a Veggie Meter optical skin scanner, which uses Raman Spectroscopy.
The Veggie Meter assesses frequency changes in reflected light to calculate carotenoid presence in the skin and has been validated as a non-self-report, non-invasive measure associated with serum carotenoid levels and self-report measures of fruit and vegetable consumption.
Each participant's index finger was scanned three times and the mean of the three measures was recorded for use in data analysis.
Veggie Meter scores have a possible range of 0-800, with higher scores indicating better diet quality.
|
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
|
Body Mass Index (BMI)
Lasso di tempo: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
Participant height (without shoes) was collected using a stadiometer and participant weight (without shoes) was collected using a calibrated digital scale.
Height and weight were used to compute a continuous measure of BMI (kilograms per square meter).
|
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
|
Systolic Blood Pressure (SBP)
Lasso di tempo: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
Blood pressure was measured with a digital blood pressure device with the participant seated and arm elevated to place the cuff approximately at heart height.
Two blood pressure measurements were taken, waiting at least one minute between readings.
If there was a >5mmHg difference between the first and second reading, an additional two measurements were taken.
The mean of the two (or four) measurements was recorded and used in analysis.
|
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
|
Diastolic Blood Pressure (DBP)
Lasso di tempo: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
Blood pressure was measured with a digital blood pressure device with the participant seated and arm elevated to place the cuff approximately at heart height.
Two blood pressure measurements were taken, waiting at least one minute between readings.
If there was a >5mmHg difference between the first and second reading, an additional two measurements were taken.
The mean of the two (or four) measurements was recorded and used in analysis.
|
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
|
Total Cholesterol
Lasso di tempo: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
Through finger prick blood collection, point of care tests were used to collect lipids using a commercial lipid panel kit and Cholestech LDX analyzer.
|
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
|
High-Density Lipoproteins (HDL)
Lasso di tempo: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
Through finger prick blood collection, point of care tests were used to collect HDL using a commercial lipid panel kit and Cholestech LDX analyzer.
|
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
|
Low-Density Lipoproteins (LDL)
Lasso di tempo: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
Through finger prick blood collection, point of care tests were used to collect LDL using a commercial lipid panel kit and Cholestech LDX analyzer.
|
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
|
Triglycerides
Lasso di tempo: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
Through finger prick blood collection, point of care tests were used to collect triglycerides using a commercial lipid panel kit and Cholestech LDX analyzer.
|
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
|
Glucose
Lasso di tempo: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
Through finger prick blood collection, point of care tests were used to collect random (non-fasting) blood glucose.
|
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
|
Diabetes Self-Efficacy (DMSES)
Lasso di tempo: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
The Diabetes Management Self-Efficacy Scale (DMSES) was used to measure patient's confidence in managing their diabetes.
The DMSES assesses self-reported confidence in managing multiple aspects of their diabetes.
The item reponses range from 1 (not at all confident) to 10 (totally confident) and are averaged to generate composite scores, with higher scores indicating higher levels of self-efficacy.
|
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
|
Diabetes-Related Distress (PAID-5)
Lasso di tempo: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
The Problem Areas in Diabetes scale (PAID-5) was used to measure diabetes-related distress.
The PAID-5 consists of 5 items to assess self-reported diabetes-related emotional distress, including feeling scared or depressed.
Item responses range from 0 (not a problem) to 4 (serious problem) and are summed to produce an overall composite score, with a total score of 8 or higher indicating possible diabetes-related emotional distress.
|
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
|
Food Insecurity
Lasso di tempo: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
Food insecurity was assessed using the 2-item Hunger Vital Sign.
Affirmative answers ("Often True" or "Sometimes True") to either of the 2 screener items indicates food insecurity.
Food insecurity was treated as a binary outcome (0=food secure, 1=food insecure).
|
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Pearl A McElfish, PhD, University of Arkansas
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 261074
- 5R01NR019487 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .